CONCERT PHARMACEUTICALS INC (CNCE)
US2060221056 - Common Stock
Concert retains breakthrough tag for hair loss therapy despite rival entry (NASDAQ:CNCE)
Concert Pharmaceuticals (CNCE) announced Wednesday that the FDA allowed it to keep the Breakthrough Therapy Designation for hair loss therapy deuruxolitinib. Read the full story here.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, ISO, TIG
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNCE, AQUA, LPTX, ALR
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, CNCE, AQUA, LPTX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HZN, ANGN, CNCE
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Sun Pharma entend acquérir Concert Pharmaceuticals pour faire progresser le traitement potentiel de l'alopécie areata
Ajoute à son portefeuille le deuruxolitinib, un inhibiteur oral des Janus kinases qui pourrait être le meilleur de sa catégorie pour le traitement de...
SHAREHOLDER ALERT: Weiss Law Reminds LPTX, CNCE, ALBO, and CINC Shareholders About Its Ongoing Investigations
/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
Sun Pharma adquire Concert Pharmaceuticals, avançando no tratamento potencial para a Alopecia Areata
Adiciona o Deuruxolitinib, possível inibidor de JAK Oral para o tratamento da Alopecia Areata, uma doença dermatológica autoimune Aproveita a infraestrutura...
Sun Pharma adquiere Concert Pharmaceuticals para avanzar en el tratamiento de la alopecia areata
Añade deuruxolitinib, un inhibidor oral de JAK potencialmente mejor de su clase para el tratamiento de la alopecia areata, una enfermedad dermatológica...
Sun Pharma erwirbt Concert Pharmaceuticals und treibt damit die Behandlung von Alopecia areata voran
Dadurch wird Deuruxolitinib, ein potenziell klassenbester oraler JAK-Inhibitor zur Behandlung von Alopecia areata, einer autoimmunen dermatologischen...
Moore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Why Concert Pharmaceuticals Stock Rocketed Higher This Week
The company is changing hands in a deal worth at least $576 million.
SHAREHOLDER ALERT: Weiss Law Investigates Concert Pharmaceuticals, Inc.
/PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Concert...
Hot Stocks: CNCE takeover deal; SRDX plunges; EDU reaches 52-week high; RIVN sets new low
RIVN set a 52-week low. CNCE jumped on a takeover deal. SRDX fell on a regulatory setback. EDU reached a 52-week high.
Shareholder Alert: Ademi LLP investigates whether Concert Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Sun Pharma
/PRNewswire/ -- Ademi LLP is investigating Concert (NASDAQ: CNCE) for possible breaches of fiduciary duty and other violations of law in its transaction with...
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, an Autoimmune Dermatological Disease Leverages Sun...
Sun Pharma to Acquire Concert Pharmaceuticals, Advancing the Potential Treatment of Alopecia Areata
CNCE Crosses Above Key Moving Average Level
CNCE Crosses Below Key Moving Average Level
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
